| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9888139 | Clinica Chimica Acta | 2005 | 7 Pages |
Abstract
We demonstrated that the introduction of the Actalyke® ACT system significantly altered our clinical practice by increasing the heparin dose required to exceed our target ACT during CPB. Prospective study to determine the effect of Actalyke® ACT system monitoring on hemostasis after cardiac surgery is merited.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Mathew Patteril, Mark Stafford-Smith, John G. Toffaletti, Barbara Phillips Bute, Carmelo A. Milano, Ian J. Welsby,